Clinical trials: Non-small-cell Lung Cancer (NSCLC)
Melanoma (Skin), Triple-Negative Breast Cancer
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to…
- Conditions
- Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma
- Trial name
- NCT05492682
- Testing
- PeptiCRAd-1, Cyclophosphamide, Pembrolizumab
- Where
- 7 sites in Germany, Italy
- Volunteers
- 15 people
- Sponsor
- Valo Therapeutics Oy
Carcinoma, Non-Small-Cell Lung, Non-small Lung Cancer
Genomic Landscape of Ceritinib
The investigators propose to conduct a retrospective study of single agent ceritinib in patients with previously untreated anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma of the lung with the sole purpose of…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-small Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT02554591
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Advanced Solid Tumors
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are solid cancers that may have spread to nearby tissue, lymph nodes and/or to distant parts of the body and that are…
- Trial name
- NCT05537740
- Testing
- BAY3375968, Pembrolizumab
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 129 people
- Sponsor
- Bayer
Lung Cancer
Second Primary Lung Cancer Cohort Study (SPORT)
Patients who have had curative treatment for lung cancer are at an increased risk of developing second primary lung cancers (and other cancers) over the next 10 years.
- Trial name
- SPORT (NCT04178889)
- Where
- United Kingdom
- Volunteers
- 850 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Head and Neck Cancer, Ovarian Cancer
Deciphering Mechanisms Underlying Cancer Immunogenicity
This trial is a translational, open-label, multicentric, prospective cohort study of 1100 patients aiming to describe the PD-1 (programmed death) expression in T cells (T lymphocytes) in different solid tumors.
- Conditions
- Head and Neck Cancer, Ovarian Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia 3
- Trial name
- DECIDE (NCT03958240)
- Testing
- Blood samples, tumor biopsy specimens and ascites samples will be collected.
- Where
- 3 sites in France
- Volunteers
- 1,100 people
- Sponsor
- Institut Claudius Regaud
Solid Tumor, NSCLC
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or…
- Conditions
- Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT07873450
- Testing
- [225Ac]Ac-FL-261
- Where
- 2 sites in United States, Australia
- Volunteers
- 208 people
- Sponsor
- Full-Life Technologies UK Limited
Non-Small Cell Lung Cancer
Septum-guided Segmentectomy for 2-3 cm Clinical Stage IA3 Peripheral Non-Small Cell Lung Cancer
This is a single-center, prospective, single-arm, open-label clinical trial evaluating the efficacy and safety of septum-guided segmentectomy in patients with 2-3 cm clinical stage IA3 peripheral non-small cell lung cancer…
- Trial name
- SGS2606 (NCT07780591)
- Testing
- septum-guided anatomical segmentectomy
- Volunteers
- 100 people
- Sponsor
- Shanghai Chest Hospital
Non Small Cell Lung Cancer
A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of single and multiple oral doses of TQ-A3334 and observe the efficacy of TQ-A3334 in combination with anlotinib capsules…
- Trial name
- NCT06507891
- Testing
- TQ-A3334 tablets, TQ-A3334 tablets + Anlotinib capsules
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
Mobile Health Application of Disease Self-Management in Non-Small Cell Lung Cancer Patients During Targeted Therapy
The study's purpose is to understand the self-management needs of patients with NSCLC receiving targeted therapy, develop a disease self- management application (mHealth Application), and explore the effect of mHealth application…
- Trial name
- NCT05611450
- Testing
- disease self-management application
- Volunteers
- 108 people
- Sponsor
- Chang Gung Memorial Hospital
Advanced Solid Tumor
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
Evaluating the efficacy of Neratinib tablets monotherapy in treating advanced solid tumors with HER2 mutations.
- Trial name
- CVL009-C2001 (NCT06519110)
- Testing
- Neratinib tablets
- Volunteers
- 60 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Non-small Cell Lung Cancer
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
The study is evaluating the safety and tolerability of Nivolumab (BMS-936558) when combined with three platinum-based doublet chemotherapy regimens (Cisplatin/Gemcitabine; Cisplatin/Pemetrexed; and Carboplatin/Paclitaxel) in…
- Trial name
- NCT01454102
- Testing
- Nivolumab, Gemcitabine, Cisplatin
- Where
- 12 sites in United States, Canada
- Volunteers
- 472 people
- Sponsor
- Bristol-Myers Squibb
Squamous Non Small Cell Lung Cancer
AZD2014 and Weekly Paclitaxel in Squamous NSCLC
Open--label, phase 2a, multi-centre, single-arm study to assess the efficacy and safety of AZD2014 and weekly paclitaxel in patients with squamous non-small cell lung cancer (NSCLC)
- Trial name
- NCT02403895
- Testing
- Open-label AZD2014, paclitaxel
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
NSCLC, Neutropenia
A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor to limit the dosage and the continuation of chemotherapy.
- Conditions
- NSCLC, Neutropenia, Febrile Neutropenia
- Trial name
- NCT01560195
- Testing
- Pegylated rhG-CSF: 100µg/kg, Pegylated rhG-CSF: 6mg
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non Small Cell Lung Cancer, Small Cell Lung Cancer
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
Hypothesis 1- Using IMRT, the radiation therapy (RT) dose can be safely escalated from 58 Gy to 74 Gy given as 6 fractions/week with concurrent chemotherapy.
- Conditions
- Non Small Cell Lung Cancer, Small Cell Lung Cancer, Thymoma, Thymus Neoplasms
- Trial name
- ESIMRT (NCT00921739)
- Testing
- Esophageal sparing IMRT
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)
The primary goal of the study is to evaluate an investigational drug's effectiveness as a treatment for Non small-cell lung cancer (NSCLC)
- Trial name
- NCT00034957
- Testing
- Investigational drug
- Where
- 12 sites in United States
- Sponsor
- Pfizer
Chemotherapeutic Agent Toxicity, Lung Cancer
Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to find the highest tolerable dose of Anvirzel (Nerium Oleander) that can be given to lung cancer patients receiving standard therapy with carboplatin and docetaxel.
- Trial name
- NCT01562301
- Testing
- Carboplatin, Docetaxel, Anvirzel
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer Stage III
A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
This is a prospective, single arm, phase II study to evaluate the efficacy and safety of Envafolimab in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not progressed after prior…
- Trial name
- NCT05414630
- Testing
- Envafolimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Cancer Hospital
Breast Cancer, Lung Cancer (Non-Small Cell)
Effectiveness of a Multimodal Outpatient Supervised Physical Activity Program to Improve Tolerance and Efficacy of Chemotherapy in Adults With Breast, Lung and Colon Cancer
This clinical study evaluates whether a supervised, multimodal therapeutic exercise program started before chemotherapy and continued during treatment can improve treatment outcomes in patients aged 35 to 65 years with breast…
- Conditions
- Breast Cancer, Lung Cancer (Non-Small Cell), Colorectal Cancer, Physical Activity
- Trial name
- PREDU (NCT07502963)
- Testing
- PREDU Exercise Program, Recommendation Exercise Program
- Where
- 3 sites in Spain
- Volunteers
- 70 people
- Sponsor
- University of Vic - Central University of Catalonia
Non Small Cell Lung Cancer
A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer
This is a randomized clinical trial of Paclitaxel (Genexol®) and Cisplatin versus Paclitaxel loaded polymeric micelle (Genexol-PM®) and Cisplatin in advanced non small cell lung cancer.
- Trial name
- NCT01023347
- Testing
- Paclitaxel (Genexol®), Paclitaxel loaded polymeric micelle (Genexol-PM®)
- Where
- South Korea
- Volunteers
- 276 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Stage IV Non-small Cell Lung Cancer
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in patients with stage IV non-squamous…
- Trial name
- NCT03559049
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.